BMS – Anthropic AI Partnership
Bristol Myers Squibb announced a strategic enterprise partnership with Anthropic to deploy Claude Enterprise across research, clinical development, manufacturing, regulatory, and commercial operations.
All categories
Wave – WVE-006 RNA Editing Update
Wave Life Sciences reported positive updated data from the RestorAATion-2 study of WVE-006, demonstrating substantial restoration of functional alpha-1 antitrypsin protein and significant reduction of toxic mutant protein in Alpha-1 Antitrypsin Deficiency (AATD).
Beam – BEAM-302 Base Editing Update
Beam Therapeutics presented updated Phase 1/2 data for BEAM-302 at ATS 2026, reinforcing the company’s in vivo base-editing platform and supporting plans for an accelerated approval strategy in Alpha-1 Antitrypsin Deficiency (AATD).
Beam – Base Editing SCD Data Update
Beam Therapeutics announced updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel), reinforcing its position as the leading base-edited cell therapy program in sickle cell disease ahead of a planned…
Agios – Mitapivat sNDA in Sickle Cell Disease
Agios Pharmaceuticals submitted a supplemental NDA to the FDA seeking accelerated approval of mitapivat for sickle cell disease, positioning the oral PKR activator in a highly competitive emerging therapeutic class.
Incyte – EHA 2026 Hematology Data
Incyte announced more than 20 hematology and oncology presentations for EHA 2026, highlighted by plenary Phase 3 frontMIND data in frontline diffuse large B-cell lymphoma (DLBCL) and new clinical data for INCA033989, a mutation-specific…
J&J – EHA 2026 Hematology Abstracts
Johnson & Johnson announced more than 30 hematology presentations for EHA 2026, including key datasets from the Phase 3 MonumenTAL-3 and MajesTEC-9 multiple myeloma studies and pivotal Phase 2/3 ENERGY data for IMAAVY in…
Inhibrx – OX40 Agonist Shows Early Benefit
Inhibrx Biosciences reported interim Phase 2 data for INBRX-106 in combination with Keytruda in first-line head and neck squamous cell carcinoma (HNSCC), suggesting potential costimulatory benefit beyond PD-1 monotherapy.
Novo – Parkinson’s Cell Therapy Transfer
Novo Nordisk has transferred a Parkinson’s disease cell therapy program to Cellular Intelligence, reflecting continued asset recycling and lifecycle extension within the advanced cell therapy ecosystem.
Fractyl – First AAV Trial in Type 2 Diabetes
Fractyl Health has received authorization in the Netherlands to initiate the first-in-human clinical trial of RJVA-001, an AAV-based gene therapy for type 2 diabetes, marking the first clinical-stage gene therapy program targeting the disease.
